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Hepatic differentiation of human‐induced pluripotent stem cells (hiPSCs) under flow conditions in
a 3D scaffold is expected to be a major step forward for construction of bioartificial livers. The
aims of this study were to induce hepatic differentiation of hiPSCs under perfusion conditions
and to perform functional comparisons with fresh human precision‐cut liver slices (hPCLS), an
excellent benchmark for the human liver in vivo. The majority of the mRNA expression of CYP
isoenzymes and transporters and the tested CYP activities, Phase II metabolism, and albumin,
urea, and bile acid synthesis in the hiPSC‐derived cells reached values that overlap those of
hPCLS, which indicates a higher degree of hepatic differentiation than observed until now. Differ-
entiation under flow compared with static conditions had a strong inducing effect on Phase II
metabolism and suppressed AFP expression but resulted in slightly lower activity of some of
the Phase I metabolism enzymes. Gene expression data indicate that hiPSCs differentiated into
both hepatic and biliary directions. In conclusion, the hiPSC differentiated under flow conditions
towards hepatocytes express a wide spectrum of liver functions at levels comparable with hPCLS
indicating excellent future perspectives for the development of a bioartificial liver system for tox-
icity testing or as liver support device for patients.
KEYWORDS
bioartificial liver, hepatic differentiation, stem cells1 | INTRODUCTION
Even though fullymatured primary human hepatocytes (PHH) exhibit all
the specific liver functions, their limited availability and loss of liver‐spe-
cific functions during culturing in vitro are still the major limitations for
their application in a bioartificial liver (BAL; Mizumoto et al., 2012;
Ordovás, Park, & Verfaillie, 2013). Therefore, porcine primary hepato-
cytes and carcinoma cell lines (HepG2, HepG2/C3A, andHepaRG) have- - - - - - - - - - - - - - - - - - - - - - - - - - -
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more, the use of the patients' own hiPSCs may allow for personalized
treatment and thereby avoiding immunological reactions. Although
hiPSC‐derived hepatocyte‐like cells have been shown to have certain
liver‐specific phenotypic characteristics and exhibit many of the liver‐
specific functions (Chen et al., 2012; Gieseck et al., 2014; Si‐Tayeb
et al., 2010; Song et al., 2009), most of these functions are expressed
at levels several magnitudes lower than in fresh liver tissue or freshly
isolated human hepatocytes (Ulvestad et al., 2013), suggesting that
improvements in the differentiation protocols are still warranted.
In most of these studies, the induced pluripotent stem cell‐derived
hepatocyte‐like cells were obtained by maturation in 2D cultures, and
the cells are loaded in a bioreactor only after maturation. Hepatic
differentiation and maturation directly in the 3D bioreactor may offer
great advantages such as overcoming the need to harvest the total
amount of cells needed for the BAL from the 2D culture and loading in
a 3D bioreactor. However, relatively few studies have investigated the
hepatic differentiation of stem cells directly in a 3D perfusion bioreactor
or BAL using embryonic stem cells (ESC; Fonsato et al., 2010; Miki, Ring,
& Gerlach, 2011; Pekor, Gerlach, Nettleship, & Schmelzer, 2015;
Schmelzer et al., 2010; Sivertsson, Synnergren, Jensen, Bjorquist, &
Ingelman‐Sundberg, 2013; Wang et al., 2012), and only three of them
used hiPSCs (Freyer et al., 2016; Giobbe et al., 2015; Luni et al., 2016).
Flow of the mediumwas shown to have beneficial effects on hepatic dif-
ferentiation of ESC and fetal liver cells and to improve liver functions of
ESC‐derived hepatocytes (Lu et al., 2015; Pekor et al., 2015; Schmelzer
et al., 2010; Yu et al., 2014). Even simple recirculation of medium in a
rotating bioreactor improved the function of the differentiated hepato-
cyte‐like cells (Fonsato et al., 2010; Wang et al., 2012). The flow may
not only physically influence the cells by creating flow forces, but it also
may improve mass as well as gas transfer between the cells and the
medium and promote the removal of waste products (Pekor et al.,
2015; Yu et al., 2014). However, in another study, perfusion inhibited
adipogenic differentiation of adipose‐derived stem cells possibly by
washing away autocrine or paracrine factors (Hemmingsen et al., 2013).
A limitation ofmany studies is the absence of a proper benchmark to
evaluate whether the cells are fully differentiated with respect to the
expression levels of liver‐specific markers and liver functions of the
generated hepatocytes. For example, many studies have not used a
benchmark at all, whereas others have used PHH cultured in vitro for
2 days or more (Iwamuro et al., 2012; Song et al., 2009; Takayama,
Inamura, Kawabata, Katayama, et al., 2012; Takayama, Inamura, Kawa-
bata, Sugawara, et al., 2012). However, it is known that PHH cultured
beyond 24–48 hr rapidly lose their phenotype and liver‐specific
functions, and using these cells as a benchmark results therefore in an
overestimation of the maturation level of the stem cell‐derived hepato-
cytes (Ulvestad et al., 2013). By contrast, fresh human precision‐cut liver
slices (hPCLS) contain hepatocytes in their natural 3D tissue‐matrix
configuration, in contact to the other liver cell types, and retain expres-
sion as well as activity of Phase I and Phase II metabolic enzymes at levels
comparable with the in vivo situation (Elferink et al., 2011). Therefore,
hPCLS can be considered the gold standard for assessing the maturation
of stem cell‐derived hepatocytes into fully differentiated hepatocytes.
Here, we differentiate hiPSC‐derived definitive endoderm (DE)
cells into hepatocytes in situ in a perfusion bioreactor system. Hepaticdifferentiation and functionality of hiPSC‐derived hepatocytes were
assessed using fresh hPCLS as benchmark for ex vivo liver, and 2D
static cultures were used to compare differentiation efficacy in 2D
static and 3D flow systems.2 | MATERIALS AND METHODS
2.1 | Differentiation of hiPSC‐DE cells into
hepatocytes under static conditions and flow
conditions
Human iPS‐derived DE cells (Cellartis Definitive Endoderm ChiPSC18,
Cat. No. Y10040) derived from human dermal fibroblasts, authenti-
cated using Short Tandem Repeat (STR), and mycoplasma free accord-
ing to quantitative PCR (see further information about this cell line on
http://www.clontech.com) were cultured and differentiated into hepa-
tocytes for 25 days according to the suppliers' recommendations in the
Cellartis Hepatocyte Differentiation Kit (Cat. No. Y30050; see Figure 1
a). Briefly, the cell culture surface (cell culture plates or scaffold) was
coated with Hepatocyte Coating (from Cellartis Hepatocyte Differenti-
ation Kit, Cat. No. Y30050) at 37 °C for 1–2 days and subsequently
washed with phosphate buffered saline solution (10 mMNa phosphate
in 0.9% NaCl, pH 7.4). DE cells were thawed and seeded in Hepatocyte
Thawing and Seeding Medium at an initial density of 2.5 × 106 cells/
scaffold and for the static references 1.5 × 105 cells/cm2 in 24‐well
plate format (using polystyrene [PS] well plates or corresponding poly-
dimethylsiloxane [PDMS]‐coated well plates, see below) in 1 ml of
medium. The DE cells were differentiated in Hepatocyte Thawing
and Seeding Medium for 2 days at 37 °C, before changing to Hepato-
cyte Progenitor Medium for another 5 days of differentiation to
hepatoblasts. The cells were then differentiated further in Hepatocyte
Maturation Medium for 4 days to immature hepatocytes and finally
matured in Hepatocyte Maintenance Medium for another 14 days of
culture to mature hepatocytes. In the static cultures, the medium was
exchanged every 2–3 days. The derivation of DE cells from iPSCs as
well as the robustness of the hepatic differentiation protocol has
already been shown before in 2D conditions on hiPSC cell lines from
different donors (Asplund et al., 2016).2.2 | Scaffolds fabrication and perfusion cell
differentiation culture
PDMS was chosen as scaffold material instead of hydrogels because
of its good biocompatibility and structural stability and possibility to
scale it up enabling production of litre‐sized scaffolds (Mohanty
et al., 2016). Random porous scaffolds (Figure 1e) were fabricated
from PDMS by using salt leaching techniques similar to that described
previously (Yuen, Su, Goral, & Fink, 2011). Hexagonal combined struc-
tured or porous scaffolds (Figure 1e) were made using a sacrificial
mould with hexagonal pattern fabricated by 3D printing using com-
mercially available water dissolvable polyvinyl alcohol (MakerBot,
USA) and packed with salt crystals as described before. The scaffolds
were treated with oxygen plasma (125 W, 13.5 MHz, 50 sccm, and
40 millitorr) to render their surfaces hydrophilic and sterilized by
FIGURE 1 (a) Schematic overview of the experimental process of differentiation of DE cells to mature hepatocytes. (b) Differentiation of induced
pluripotent stem cell (iPSC) under flow regime (500 nl/min) on flat surface for 25 days using normal concentration of differentiation factors or ½
concentration of differentiation factors. (c) Differentiation of iPSC for 19 days on polystyrene (PS) and on polydimethylsiloxane (PDMS). (d) Human
precision‐cut liver slices at 0 and 24 hr of incubation (haematoxylin–eosin staining). (e) Scaffolds and house (left panel) used for perfusion. (f)
Confocal microscopy images of iPSCS‐derived hepatocyte‐like cells. Blue is nucleus (DAPI), and red is actin staining [Colour figure can be viewed at
wileyonlinelibrary.com]
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Cellartis Hepatocyte Differentiation Kit, Cat. No. Y30050) by centri-
fugation at 300 g for 5 min and then left overnight at 37 °C. The scaf-
folds were subsequently washed with phosphate buffered saline
centrifugation at 300 g for 5 min and then left in a medium at 37 °C
for 2 hr prior to being used to experiments.
A self‐sustained perfusion system with 16 parallel reactors was con-
structed (Figure S1) holding PDMS scaffolds. The scaffold bioreactor array,
glass vials, caps, and poly(tetrafluoroethylene) tubing were sterilized by
autoclaving before assembling in a laminar flow bench. A 0.5 M NaOH
was flushed throughout the system to ensure a sterile fluidic path. The sys-
tem was subsequently flushed with sterile water and then with culture
medium. Coated scaffolds were placed in cylindrical holes in a custom built
tray. A 2.5 × 106 freshly thawed DE cells in 30 μl of HepatocyteThawing
and Seeding Medium was pipetted into each scaffold, and cells were
allowed to adhere for 3 hr at 37 °C under 95% air/5% CO2. The seeding
tray was inverted as well as placed vertically in four different positions to
allow the cells to distribute throughout the scaffolds during 3 hr. The scaf-
folds were then placed in the 4 × 4 bioreactor array of the fluidic platform,
and media were perfused through the scaffolds at flow rates of either 1 or
5μl/min. The entire systemwas incubated at 37 °C under 95%air/5%CO2.
Cells were cultured and differentiated for 25 days.2.3 | Human liver tissue
Human liver material was obtained from liver tissue of 10 individual
patients, remaining as surgical waste after reduced liver transplantation
patients, from liver tissue donated after cardiac death but not suitable
for transplantation due to the age, or from patients undergoinghepatectomy for the removal of carcinoma. This study was approved
by the Medical Ethical Committee of the UniversityMedical Centre Gro-
ningen, according to Dutch legislation and the Code of Conduct for deal-
ing responsibly with human tissue in the context of health research
(http://www.federa.org), refraining the need of written consent for “fur-
ther use” of coded‐anonymous human tissue. The procedures were car-
ried out in accordance with the experimental protocols approved by
the Medical Ethical Committee of the University Medical Centre
Groningen.
hPCLS were prepared as described previously by de Graaf et al.
(2010). The hPCLS were made about 200 μm thick and had 5‐mg wet
weight. In order to remove cell debris and to restore function, hPCLS were
preincubated in the incubator (Panasonic, USA) for 1 hr at 37 °C in a 12‐
well plate filled with 1.3 ml of Williams' Medium E (Gibco, USA) saturated
with 80%O2/5%CO2 while gently shaking 90 cycles per minute.2.3.1 | Static hPCLS culture
After preincubation, sliceswere transferred individually to a 12‐well plate
filled with 1.3 ml of Hepatocyte Maintenance Medium (from Cellartis
Hepatocyte Diff Kit; Cat. No. Y30050) saturated with 80%O2/5CO2
and supplemented with 50 μg/ml gentamycin (Invitrogen). Plates were
gently shaken at a rate of 90 cycles per minute in the incubator at 37 °C.2.3.2 | hPCLS culture under flow condition
After preincubation, slices were transferred individually into small
micro‐chambers of PDMS biochips. The fabrication process of the bio-
chip, as well as a schematic view of the biochip set‐up, was extensively
described before (van Midwoud, Groothuis, Merema, & Verpoorte,
1276 STAROKOZHKO ET AL.2010). Slices were embedded in Matrigel (BD Biosciences, Bedford,
MA, USA) as described previously, and the biochips were perfused
with 2 times diluted Hepatocyte Maintenance Medium from Cellartis
Hepatocyte Diff Kit supplemented with 50 mg/ml gentamycin at
10 μl/min flow in a humidified incubation chamber saturated with a
mixture of 95%O2/5%CO2 as described in detail before (van Midwoud,
Merema, Verweij, et al., 2011). Viability of hPCLS was assessed by
analysis of ATP content and morphological examination after 0 and
24 hr. More details are provided in the Supporting Information.2.4 | Imaging and confocal microscopy
Phase contrast images of 2D flow cultures and fluorescence‐based
imaging of the scaffolds were acquired by a Zeiss Axio Observer as
described in detail in the Supporting Information. Confocal acquisitions
of the scaffolds were performed using a Zeiss LSM 700 module in the
Axio Imager M2 upright microscope using a 40×/1.20 W Korr C‐Apo
objective. More details are provided in the Supporting Information.2.5 | Functional characterization of hiPSC‐derived
hepatocytes and hPCLS
2.5.1 | Phase I metabolism
To test the activities of several different CYP isoenzymes, hPCLS and
cells in perfused and static systems were exposed for 1–3 hr to a drug
cocktail containing 10 μM phenacetin (CYP1A), 10 μM bupropion
(CYP2B6), 50 μMmephenytoin (CYP2C19), 10 μMdiclofenac (CYP2C9),
10 μMbufuralol (CYP2D6), and 5 μMmidazolam (CYP3A) in Hepatocyte
Maintenance Medium without phenol red and supplemented with 2 mM
L‐glutamine and antibiotics (50 mg/ml gentamycin for hPCLS and 0.1%
penicillin and streptavidin for cells). Medium was collected and stored
at −80 °C until further analysis. Metabolite concentrations were mea-
sured at Pharmacelsus (Germany) by liquid chromatography–mass spec-
trometry according to in house protocols. Themetabolite productionwas
normalized per milligram protein and per hour.2.5.2 | Phase II metabolism
For Phase II metabolism studies, hPCLS and cells in perfused systems
or in static condition were exposed to 100 μM of 7‐hydroxycoumarin
(7‐HC; Sigma‐Aldrich, St.Louis, MO, USA) for 1–3 hr. Medium was col-
lected at outlet tubes or from the incubation medium and stored at
−20 °C until further analysis, using 7‐HC, 7‐HC‐glucuronide, and 7‐
HC‐sulfate as standards. The metabolite production was normalized
per milligram protein and per hour.2.6 | Gene expression
Total cellular RNA from cells or PCLS was purified by using the RNeasy
Micro kit (Qiagen, 74004) or using Maxwell 16 LEV simplyRNA Tissue
Kit (Promega, USA), respectively. The RNA was converted to cDNA
using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, 4374966), and quantitative real‐time PCR was conducted
using the TaqMan Gene Expression Assays (Applied Biosystems
4331182). More details are provided in the Supporting Information.2.7 | Statistical analysis
Four independent experiments were performed with four batches of
DE cells from one donor and hPCLS from seven different human
donors. Because the number of donor livers for slices and number of
donors for stem cells are limited, and inter‐individual variations are
large in the human population, we conclude on the differentiation of
the cells by comparing the range of expression or activity rather than
the mean or median values.
Additional methods can be found in the Supporting Information.3 | RESULTS
3.1 | Differentiation of DE cells into hepatocyte‐like
cells under 3D flow condition
Differentiation of hiPSC‐derived DE cells into hepatocytes was per-
formed in perfused 3D bioreactors with highly porous 3D PDMS scaf-
folds and for comparison in conventional 2D cultures in PS wells or
PDMS‐coated wells. Frozen DE cells were seeded at a density of
2.5 × 106 cells per scaffold and differentiated into hepatocytes as illus-
trated in Figure 1a. Differentiation under flow on 2D surface showed
very good morphology of differentiated cells (Figure 1b), provided that
the amount of differentiation factors was reduced by 50%, because
100% differentiation factor concentration results in poor cell adhesion
during flow (Figure S2, left panels). Cells differentiated on PS and
PDMS, respectively, under static conditions showed similar morphol-
ogy (Figure 1c; Figure S3). It was not possible to obtain bright field
images of the cells in the 3D scaffold due to the poor optical character-
istics of the scaffold.
The cells adhered typically in clusters in the scaffolds (Figure 1f) at
a relatively low overall final cell density (200.000–300.000 cells/scaf-
fold) as determined by visual inspection (Figure S4) and measurement
of protein content (Figure S5) in the scaffold. As DE cells and differen-
tiated hepatocytes adhere well to PDMS (Figure S4), the relatively low
number of adhering cells to the scaffold is likely due to difficulties to
seed the cells in the scaffolds, although seeding was performed by
rotating the scaffolds in six different directions with 30‐min incubation
in each direction. Calculations indicate that a scaffold has a surface
area of approximately 10 cm2 (Figure S6), and thus, the cells in the
3D scaffold had an effective cell density of 20,000–30,000 cells/cm2,
which is lower than the corresponding 2D static cultures (usually
80,000–100,000 stem cell‐derived hepatocytes/cm2; data not shown).
However, as determined by visual inspection, the cells adhered typi-
cally in clusters, and therefore, the local cell densities were probably
higher.
Differentiation of hiPSC‐derived DE cells loaded in the scaffolds
was performed at a flow rate of 1 μl/min (exchange rate every
50 min) and 5 μl/min (exchange rate every 10 min). It was calculated
that in both flow regimens, shear forces were very low (1.1e‐4 dyn/
cm2 or less; Figures S7 and S8). Furthermore, the exchange rate of
once per 10 min was shown to be compatible with differentiation into
hepatocytes in 2D flow cultures (Figure S2) and has previously shown
to support differentiation of adipose‐derived stem cells into adipo-
cytes using conditioned medium (Hemmingsen et al., 2013).
FIGURE 3 Summary of the comparison of the gene expression levels
between the differentiated cells and the human precision‐cut liver
slices (hPCLS) as benchmark from Figure 3. The different grades of
colour in the chart represent the gene expression levels in the human‐
induced pluripotent stem cells‐derived hepatocytes relative to the
gene expression levels in hPCLS as follows: Black = all individual data
of the cells are higher than those in hPCLS; dark grey = the individual
data of the cells are higher than or in the higher range of those of
hPCLS; Middle grey = all data of the cells are in the same range as
those of hPCLS; light grey = the individual data of the cells are lower
than or in the lower range of those of hPCLS; white = all individual data
of the cells are lower than those of the hPCLS.
PDMS = polydimethylsiloxane; PS = polystyrene
STAROKOZHKO ET AL. 12773.2 | Comparison of gene expression of hepatocyte
markers of human iPSC‐derived hepatocytes and hPCLS
We investigated the hepatic differentiation of hiPSC‐derived DE cells
in the 3D scaffold at two different flow rates, 1 and 5 μl/min, and in
two different scaffold designs (Figure 1e) and compared the results
with cells differentiated under static 2D conditions in standard PS well
plates or in well plates coated with a PDMS layer. hPCLS were used as
a benchmark for cells differentiated in the scaffold under perfusion.
hPCLS were prepared from 10 individual livers of human donors, aged
20–73 years (60% female) as described (de Graaf et al., 2010). Due to
the limited amount of liver material, not every test was performed on
all donor livers. The morphological appearance and ATP content of
the hPCLS after a preincubation of 1 hr to restore ATP levels (0 hr)
and after 24 hr of incubation indicated that the slices were viable.
ATP levels were 9.7 ± 1.3 and 8.24 ± 0.76 pmol/μg protein at 0 and
24 hr, respectively (mean ± standard error of the mean). Morphology
showed intact liver tissue at 0 and after 24 hr of incubation (Figure 1d).
The gene expression of the liver‐specific genes of the cells differ-
entiated under the conditions outlined above and the hPCLS is
depicted in Figure 2. A summary based on classification of gene
expression into broader groups is presented in Figure 3. WhenFIGURE 2 Expression of different hepatic genes by definitive endoderm (DE) cells cultured and differentiated under different conditions. Data are
given for each individual sample to appreciate the variation within each condition and the overlap between the different conditions. Data are
presented as Ct values of the respective genes normalized to Ct values of the housekeeping gene CREBBP. Results are from four independent
differentiation experiments and seven donors. Due to poor RNA yield, some genes where only analysed in two (P‐gp) or three (CK7, BSEP, and
BGP) of the cultures. PCLS = precision‐cut liver slices; PDMS = polydimethylsiloxane; PS = polystyrene [Colour figure can be viewed at
wileyonlinelibrary.com]
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most of the CYP genes, the expression of the epithelial biliary cell
markers (CK7 and BGP), and the drug transporter ABCB1 (multidrug
resistance protein, P‐gp) in the cells were in the range of that seen
in hPCLS. Large differences in gene expression were observed for
the genes CAR, ALB, and BSEP. These genes were clearly expressed
lower in differentiated cells compared with hPCLS. These three genes
were, however, expressed higher in differentiated cells than in the DE
cells (Figures 2 and 3). Furthermore, the differentiated cells showed
higher expression of AFP and HNF4a than the hPCLS. The differenti-
ated cells on PS therefore had a mixed phenotype, where some genes
suggest a partly to fully maturated phenotype (HNF4a, CYP3A4, 3A5,
3A7, and 2B6 and P‐gp), whereas others suggest a less mature phe-
notype (ALB, AFP, CAR, and BSEP). In addition, maturation of a part
of the cells into biliary epithelial cells is suggested by expression of
CK7 and BGP.
Differentiation on the scaffold material PDMS in static cultures
had only a minor impact on the gene expression compared with cells
on PS; all genes showed overlapping expression in cells on PDMS
and PS, respectively (Figures 2 and 3).
Flow modulated the gene expression of differentiated cells only to
a small extent, with 5 μl/min performing slightly better than 1 μl/min
for CYP 3A4 and 2B6. Flow also modulated the ALB and AFP expres-
sion; the ALB expression was suppressed by flow compared with the
corresponding static cultures. The AFP expression was lowest in cells
exposed to the 5 μl/min perfusion compared with static and perfusion
with 1 μl/min but did not result in the very low levels observed in
hPCLS (Figures 2 and 3).FIGURE 4 Phase I metabolite production of midazolam, phenacetin, di
pluripotent stem cells‐derived hepatocytes and human precision‐cut liver s
are expressed as pmol·min−1·mg−1 protein. Results are from three independe
liver slices; PDMS = polydimethylsiloxane; PS = polystyrene [Colour figure3.3 | Liver functions
Phase I and Phase II metabolic activities, albumin, urea, and total bile
acid production were analysed in hPCLS and the hiPSC‐derived hepa-
tocytes for each of the different conditions described above.3.3.1 | Phase I metabolism
Differentiated hiPSC‐derived DE cells as well as hPCLS were exposed
to the substrates under both static and flow conditions to account for
possible effects of flow on metabolism. The metabolic activities in the
hPCLS showed large inter‐donor variations as expected, as inter‐indi-
vidual differences in drug metabolism are well described. On the other
hand, the source of the human liver tissue or age of the patients (aged
from 20 to 73 years) did not have an effect on and did not correlate
with the functional capacities of the liver.
Overall, the hPCLS showed similar metabolic activity when cul-
tured under flow or in static conditions, although a lower metabolic
activity was found for CYP3A and CYP2B6 activity under flow
(Figure 4). These differences may be explained by binding of the lipo-
philic substrates midazolam and bupropion to the PDMS of the biochip
(van Midwoud, Merema, Verpoorte, et al., 2011), although it cannot be
excluded that the perfusion conditions may have influenced the meta-
bolic activity.
The hiPSC‐derived hepatocytes differentiated under flow condi-
tions as well as under static conditions showed overlapping activities
of CYP3A, CYP1A, CYP2C9, CYP2D6, and CYP2C19 with the hPCLS
(Figure 4). However, at a flow of 1 μl/min, somewhat lower activities
of CYP2C9 and CYP2C19 were found compared with a flow of 5 μl/clofenac, bufuralol, bupropion, and mephenytoin by human‐induced
lices cultured in static or under flow conditions. The individual values
nt differentiation experiments and seven donors. PCLS = precision‐cut
can be viewed at wileyonlinelibrary.com]
STAROKOZHKO ET AL. 1279min. CYP2B6 showed very low activities in cells compared with hPCLS
irrespective of perfusion or static culture conditions. The overlap
in activities of most of the CYP isoforms, with exception of CYP2B6,
in the differentiated cells with those in hPCLS under flow indicates
a high degree of hepatocyte drug metabolic function in the differenti-
ated cells.3.3.2 | Phase II metabolism
Differentiated cells exhibited high uridine UDP‐glucuronyltransferase
and sulfotransferase activities when exposed to 7‐HC (Figure 5). Both
Phase II activities were higher in hiPSC‐derived hepatocytes at a flow
of 5 μl/min than at 1 μl/min. Although the activities in cells cultured
under static conditions were similar to those in hPCLS static cultures,
the 7‐HC‐glucuronide production by cells cultured at 5 μl/min flow
in both hexagonal and random scaffolds was on average twofold
higher than in liver slices at flow conditions. In addition, the sulfation
rate of 7‐HC resulting in 7‐HC‐sulfate was 30–40‐fold higher in cells
differentiated under flow condition compared with differentiation
under static condition and the hPCLS.FIGURE 6 Albumin production by human‐induced pluripotent stem
cells‐derived hepatocytes and human precision‐cut liver slices
cultured in static or under flow conditions. The individual data values
are expressed as ng/hr/mg protein. Results are from three
independent of differentiation experiments and seven donors.
PCLS = precision‐cut liver slices; PDMS = polydimethylsiloxane;3.3.3 | Albumin production
Albumin production by the hiPSC‐derived hepatocytes was overlap-
ping with the lower range of that of hPCLS (Figure 6). No difference
was observed between the two types of scaffolds at both flow rates
or between static and perfusion cultures.
PS = polystyrene [Colour figure can be viewed at wileyonlinelibrary.
com]3.3.4 | Bile acid secretion and urea synthesis
Bile acid secretion by the hiPSC‐derived hepatocytes was at the same
level of 25–30 pmol·hr−1·mg−1 protein in cells differentiated under
static conditions for 22 or 24 days as in hPCLS (Figure S9). We could
not detect bile acids in the samples of the outflow medium obtained
of the scaffolds. This was probably because the excreted compounds
were highly diluted by the perfusion flow rate. The observed total bile
acid secretion of 25–30 pmol·hr−1·mg−1 protein by differentiated cells
or hPCLS would result in a concentration of about 20–100 pmol/ml atFIGURE 5 Production of 7‐hydroxycoumarin
glucuronide (HC‐G; left panel) and 7‐
hydrocycoumarine sulfate (HC‐S; right panel)
from 7‐hydroxycoumarin by human‐induced
pluripotent stem cells‐derived hepatocytes
and human precision‐cut liver slices cultured
in static or under flow conditions. The
individual values are expressed as pmol·hr
−1·mg−1 protein. Results are from three
independent differentiation experiments and
seven donors. PCLS = precision‐cut liver
slices; PDMS = polydimethylsiloxane;
PS = polystyrene [Colour figure can be viewed
at wileyonlinelibrary.com]a flow rate of 1 and 5 μl/min, respectively, in the BAL, which is below
the detection limit of the bile acid assay.
On average, the urea production by hiPSC‐derived hepatocytes
was below or in the lower range of that of hPCLS (0.06–7.6 μg·hr
−1·mg−1 protein for hiPSC‐derived hepatocytes and 1.6–11.9 μg·hr
−1·mg−1 protein for hPCLS; Figure S10). Cells differentiated at 5 μl/
min flow and under static conditions tended to show higher urea
1280 STAROKOZHKO ET AL.synthesis (0.3–7.6 μg·hr−1·mg−1 protein) than those differentiated
under 1 μl/min flow (0.06–0.55 μg·hr−1·mg−1 protein).4 | DISCUSSION
We have obtained highly differentiated hepatocytes from hiPSCs
under flow conditions in a BAL. To assess their differentiation status,
we compared the expression and function of the cells in this BAL
model with fresh human liver slices that have in vivo‐like activities
(de Graaf et al., 2010; van Midwoud, Merema, Verpoorte, et al.,
2011) and found as yet unprecedented liver functions in the differen-
tiated cells. Moreover, we found that DE cells can be successfully dif-
ferentiated into hepatocyte‐like cells in a 3D scaffold in a bioreactor
under flow conditions, to a similar or only slightly better differentiation
grade than under static 2D conditions, especially with respect to Phase
II sulfation activity and a lower AFP expression, which can make the
production of a BAL easier and more effective in the future.
hiPSC‐derived cells differentiated under flow in a 3D bioreactor
resulted in a BAL model with overlapping Phase I metabolism (except
for CYP2B6) and similar or higher Phase II metabolism, compared with
fresh human liver slices. Urea production was present in the hiPSC but
was below or in the lower range of the hPCLS. However, the capacity
of urea production in the BAL from externally added ammonia, in order
to mimic ammonia from extrahepatic tissues, was not assessed
because no ammonia was added to the medium. Further studies with
exposure to extracellular ammonia are needed to show the ability of
the cells to detoxify ammonia, which is important for patients with liver
diseases where high concentrations of neurotoxic ammonia are
detected. Bile acids were produced by hiPSC‐derived hepatocytes at
the same rate as in fresh tissue slices. The gene expression of P‐gp in
hiPSC‐derived hepatocytes was shown to be higher than in hPCLS,
which is remarkable as a 10–20‐fold lower expression was found in
differentiated hiPSC compared with human hepatocytes by Lu et al.
(2015). However, the gene expression of BSEP in the differentiated
cells was lower than in the hPCLS. The hiPSC‐derived cells also
expressed both CK‐7 and BGP, similar to the hPCLS, indicating that
in addition to the hiPSC‐derived hepatocytes, also some biliary epithe-
lial cells are present. This bipotent differentiation potential of iPSC‐
derived hepatic progenitor cells was also found previously (Freyer
et al., 2016; Yanagida, Ito, Chikada, Nakauchi, & Kamiya, 2013). The
albumin secretion of stem cell‐derived hepatocytes achieved here is
similar to hiPSC‐derived hepatocytes found by Gieseck et al. (2014)
and 10–100‐fold higher than in human ESC‐derived hepatocytes (Miki
et al., 2011) and 3–40‐fold higher than mouse iPSC‐derived hepato-
cytes (Iwamuro et al., 2012) but lower than in fresh tissue slices.
Although the mRNA expression was high for HNF4a indicating hepatic
differentiation and low for CYP3A7, which is a fetal enzyme with low
expression in the adult liver, the relatively high expression of the fetal
protein AFP indicates that maturation of the cells is not fully complete.
This has also been observed by others (Chen et al., 2012; Freyer et al.,
2016; Gieseck et al., 2014; Iwamuro et al., 2012; Kim et al., 2015;
Sasaki et al., 2013). It still needs to be addressed how relevant this is
for the functioning of the BAL in patients who need liver support or
for toxicity testing. Taken together, these results show that hiPSCdifferentiated under static conditions as well as under flow in a scaf-
fold have liver functions close to those in fresh human liver tissue.
The significant improvements with respect to liver functions of the dif-
ferentiated cells presented here compared with other studies could be
due to better differentiation protocols, whereas the difference
between the cells differentiated under 2D static and 3D perfusion con-
ditions could be ascribed to better nutrient delivery and waste
removal.
Most studies have used PHH cultured in vitro for 1–3 days as
benchmark for hepatic activity (Gieseck et al., 2014; Lu et al., 2015;
Takayama, Inamura, Kawabata, Katayama, et al., 2012; Takayama,
Inamura, Kawabata, Sugawara, et al., 2012; Ulvestad et al., 2013).
Because PHH functions decrease rapidly and drastically (10–1000‐fold
after 48 hr culture) during in vitro culture (Ulvestad et al., 2013), the
use of these PHH as standard tends to overestimate the metabolic
function of hiPSC‐derived hepatocytes. Therefore, the comparison of
those data with our study is difficult. Moreover, comparison of the
metabolic activity data between different studies is further hampered
by the fact that the substrate concentrations and experimental condi-
tions used are largely different. Fresh human PCLS, on the other hand,
show similar metabolic activity as the fresh PHH and give a good rep-
resentation of liver functions in vivo (Asplund et al., 2016). Even
though nowadays it is possible to culture PHH for several days with
preservation of their metabolic capacities in certain culture conditions,
none of the above‐mentioned studies have shown that the appropriate
measures have been taken to maintain PHH functions. The only three
published studies that used fresh hepatocytes or hepatocytes cultured
for maximally 24 hr as a control are the study of Ulvestad et al. (2013),
Freyer et al. (2016), and Meier et al. (2017). Comparison of the results
of those studies with our data shows that the CYP3A, CYP2C9, and
CYP1A activities of hiPSC‐derived hepatocytes in our study were 10
to several hundred folds higher. In the study of Freyer et al., no
CYP2C9 activity at all was detected in the derived hepatocytes. We
were the first to measure Phase II metabolism in hiPSC and found that
glucuronidation was comparable with PCLS, but sulfation was remark-
ably higher after differentiation under flow, which requires further
studies.
The gene expression of CYP‐enzymes and their activity varied
notably between donor livers. This variation is very well known in
the human population, which is among others a result of polymor-
phisms and induction by environmental and physiological factors. For
example, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2B6, and
CYP3A4 are known to be polymorphic and highly inducible enzymes
in human (Zhou, Liu, & Chowbay, 2009). With this in mind, it is note-
worthy that the gene expression and enzyme activities in the hiPSC‐
derived cells overlapped in most cases with those in the hPCLS, with
a few discrepancies noted below. For example, the CYP3A5 gene
was higher expressed in hiPSC‐derived hepatocytes compared with
hPCLS, whereas CYP3A4 gene expression only reached up to the
lower range of human livers (Figure 2). The fact that CYP3A4 and
3A5 have strongly overlapping substrate specificities (Emoto &
Iwasaki, 2006) may explain why the total CYP3A metabolism of mid-
azolam was similar in hiPSC‐derived hepatocytes and hPCLS
(Figure 4). Although the gene expression of CYP2B6 in the differenti-
ated cells was in the lower range of hPCLS, possibly due to low CAR
STAROKOZHKO ET AL. 1281expression, the activity of this enzyme was at least 10 times lower in
hiPSC‐derived hepatocytes than in hPCLS indicating a post‐transcrip-
tional regulation. Future research will be focused to improve the as
yet under‐expressed CAR‐mediated pathway.
We found a limited influence of the flow rate on the hepatic
differentiation of hiPSC in the BAL. A flow of 5 μl/min resulted in a
slightly better hepatocyte differentiation and maturation than the
1 μl/min flow. This might be explained by the better nutrient and
oxygen supply and removal of waste metabolites at the higher flow
rate. Also, the type of scaffold had no obvious impact on the
differentiation.
In conclusion, most of the drug metabolism enzyme activities of
the developed hiPSC‐based BAL were in the same order of magnitude
as in the fresh human tissue, which is an important achievement in
liver tissue engineering and is thus promising for future applications
in drug metabolism and toxicity testing. A limitation of this study is
that besides hepatocytes and biliary epithelial cells, which were
present in the developed BAL according to gene expression profiling,
no non‐parenchymal cells are present yet. Inclusion of non‐parenchy-
mal liver cells is essential in the development of a fully functional BAL
and will be a future step in this field. Also, for future toxicity tests, it
is necessary to add these other liver cell types, as it is well known
that these non‐parenchymal cells play an important role in drug‐
induced liver injury. Moreover, future experiments with more donor
individuals for both iPSC and PCLS will help to better estimate the
variation in the population as well as the robustness of the differenti-
ation protocol. Finally, future studies should show the BAL's detoxifi-
cation capacities.
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Figure S1. System description. A: Parts of the 3D perfusion system. B:
Render of assembled 3D perfusion system. C: Picture of a perfusion
system with tubes and vials.
Figure S2. Effect of concentration of signaling factors on cell mor-
phology at flow conditions. Left panels: low magnifications, right
panels high magnifications. DE cells were cultured and differentiated
at 2D flow conditions in a chamber having dimensions of 1.5 mm (w)
× 6 mm (l) × 0.5 mm (h). The concentration of signaling factors was
either the normal used and optimized for static culture conditions or
½ the normal concentration but otherwise a full base medium. The
cells were perfused at two different flow rates, 250 nL/min or
500 nL/min, corresponding to an exchange of the medium in the
entire chamber every 20 and 10 minutes. Phase contrast images
acquired at day 25. The shown images are a representative area of
one chamber out of 4 chambers for each condition. A better cell
attachment and less dead/floating cells were observed at perfusion
with medium supplemented with half of the normal concentration
of signaling factors compared to perfusion with medium supple-
mented with the normal concentration of signaling factors.
Figure S3. Cell morphology of differentiating cells at static condi-
tions. Phase contrast images were acquired at day 9, 15, and 19.
The cell morphology was very similar between the PDMS scaffold
material and the PS conventional surface substrate, although some
larger cells were observed on PDMS)
STAROKOZHKO ET AL. 1283Figure S4. Microscopy imaging of hiPSC‐derived DE cells cultured
and hepatic differentiated inside a porous scaffold at perfusion con-
ditions: Image at day 22 after cell seeding of the middle of a cross‐
sectioned scaffold. A) Scan of entire cross‐sectioned scaffold show-
ing cell distribution. Höechst stained cell nuclei in blue color. B)
Close‐up view of cell distribution with Höechst stained cell nuclei.
The homogenous blue fields in the image are likely not cells but
reflections within the scaffold. The fluorescence image is merged
with a phase contrast image of the scaffold. C) Calcein‐AM live‐
stained cells in green.
Figure S5. Determination of protein content in the BAL. DE cells
were loaded into the BAL as described in material and methods.
Three replicates of the four investigated BALs (two different scaffold
designs and two different flow conditions), where prepared and cul-
tured for one week. Scaffolds with cells were perfused with
Dulbecco's Phosphate Buffered Saline with MgCl2 and CaCl2 (Sigma
D8662) for 30 min to remove protein containing medium and then
transferred to an 1.5 mL Eppendorf tube with 0.5 mL 0.2 M NaOH.
To enhance distribution of NaOH within the scaffold, the tubes
were vortexed for 30 seconds three times with 10 minutes incuba-
tion between each vortex. The tubes were incubated over night at
4°C. To enhance the release of cell material from the scaffold into
the NaOH, the tube was again vortexed for 3 X 30 seconds with
10 minutes incubation between each vortex, and then centrifuged
at 500 x g for 5 minutes. The supernatant was diluted 1:1 with
milliQ water to 0.1 M NaOH. The protein content was measured
by the use of the Pierce BCA Protein Assay Kit (cat. no. 23227)
according to the supplier's microplate procedure. The absorbance
was read at 570 nm and protein calculated based on a standard
curve for bovine serum albumin. The results showed that the vari-
ance between the same type of scaffold was limited. If it is assumed
that 0.1 mg protein corresponds to 100.000 cells (Anders Aspegren,
personal observations), each BAL contains about 200.000–270.000
cells. This corresponds well with theoretical calculations that there
can be a maximum of about 600,000–1,000,000 cells per BAL (see
Supplementary Figure S6).
Figure S6. Theoretical calculations of the surface area of a scaffold.
Two estimates were made: Estimate 1 was based on an idealized
network of cubes that are connected and then surrounded by
PDMS. The calculation involved trying to find out how many salt
cubes that can fit into the volume of the scaffold and then calculate
the surface area by taking the number of salt particles multiplied by
the total surface of one salt particle. The side of a salt cube is
approximately 0.35 mm as determined by scanning electron micros-
copy investigations. The distance to the next salt particle is esti-
mated to be 0.1 mm (can also be larger) meaning that a salt crystal
takes up about 0.45*0.45*0.45 = 0.091125 mm3 including the sur-
rounding PDMS. The cylinder volume (Figure 1C) is
r2*pi*h = 3*3*pi*5 = 141 mm3. 141/0.091125 = 1556 particles.
The surface area of a salt particle is 0.35*0.35*6 = 0.735 mm2.
1556*0.735 = 11.39 cm2. However because the salt crystals need
to touch each other in order to form a network, some of the areais lost. In the idealized situation, each cube loses about 1.5 sides in
surface area as it shares that area with other salt crystals. Therefore
the area is estimated to be 11.39*9/12 = 8.5 cm2 In Estimate 2 we
used the measured porosity (determined to be 65%) of a random
scaffold as input parameter and calculated the number of salt mole-
cules that could fit into pores with a total volume of 0.65 multiplied
by the scaffold volume: r2*pi*h*0.65 = 3*3*pi*5*0.65 = 92 mm3. Vol-
ume of salt particle is 0.35*0.35*0.35mm3 = 0.042875 mm3. Number
of salt particles in scaffold are 92/0.042875 = 2145 particles. Num-
ber of particles multiplied by the surface of each salt cube
(6*0.35*0.35mm2 = 0.735 mm2) = total surface volume:
1577 mm2 = 15.8 cm2. However, just as in the case above, some
of the sides of the cubes are shared between each sugar cube. Using
the estimate above, it is suggested that the surface area is
15.8 cm2*9/12 = 11.85 cm2. In this case, the surface area is esti-
mated to be about 12 cm2, which is close to Estimate 1 of
11.39 cm2. For simplicity we estimate the surface of a scaffold to
10 cm2 (1000 mm2).
Figure S7. Evaluation of shear stress acting on the 3D scaffold at
the microscale. Velocity profile (a) and pressure gradient (b) within
the bioreactor as well as in the 3D scaffold. Different COMSOL sim-
ulations were performed to calculate the shear stress that cells sense
within the 3D scaffold. The first analysis was made at the macro
scale, evaluating the velocity field and pressure gradient in the reac-
tor as well as in the 3D porous scaffold.
Figure S8. Velocity profile (a) and shear stress (b) profile inside of a
single channel having a pore diameter of 200 μm within the 3D
porous scaffold. The model shows that with a pore diameter of
200 μm the shear stress acting on the wall is 1.2·10−5 N·m−2, which
is beyond the shear stress limit that leads hepatocytes to death. To
evaluate the magnitude of the shear stress acting on the walls of the
porous channels within the 3D scaffold, an analysis at the micro‐
scale was assessed.
Figure S9. Bile acid production by hiPSC‐derived hepatocytes and
human PCLS. Graph represents mean values ± SEM. Total bile acid
(TBA) content was measured using the Total Bile Acid kit (Diazyme
Laboratories, Poway, CA, USA) in medium after 24 h incubation
(static cultures) or 24 h perfusion (perfused cells and slices). 1 ml
of medium was concentrated 10 times using the CentriVap Bench-
top Vacuum Concentrator at 35°C (Labconco, Kansas City, MO,
USA). TBA content was determined according to the manufacturer's
protocol of the TBA kit with a few modifications. Conjugated cholic
acid (50 μM) was used as a calibrator. Measurement was performed
at 37°C in a 96‐well plate in the Synergy HT plate reader (BioTek,
Winooski, VT, USA). The absorbance was read at 405 nm at 5 and
30 min. The TBA production is expressed as median with interquar-
tile range.
Figure S10. Urea production. Urea concentrations in the medium
were measured using the Urea Assay Kit (Abnova, Taiwan). Medium
samples from differentiated cells and PCLS flow and static cultures
were concentrated 10 times before measurement using the
CentriVap Benchtop Vacuum Concentrator at 35°C. Urea content
1284 STAROKOZHKO ET AL.was determined according to the manufacturer's protocol of the
Urea Assay kit with a few modifications. Accordingly, 25 μL of sam-
ples were added to each well and incubated for 30 min at room
temperature with a reagent mix. The absorbance was read at
430 nm and urea levels calculated based on standard curve of urea
standard provided with the kit and expressed as μg urea produced
per h, per mg total protein. Data are expressed as individual values.How to cite this article: Starokozhko V, Hemmingsen M,
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